ライフサイエンスコーパス: calprotectin

1 nd manganese chelation by neutrophil-derived calprotectin.

2 robial peptides RegIIIbeta, RegIIIgamma, and calprotectin.

3 in S100A9(-/-) mice by injecting recombinant calprotectin.

4 binding of Mn(II) to the His6 site of human calprotectin.

5 e inflamed gut was rescued in the absence of calprotectin.

6 of serum C-reactive protein (CRP) and fecal calprotectin.

7 e antibiotic sensitivities of spirochetes in calprotectin.

8 kers of inflammation in stool, such as fecal calprotectin.

9 ch comes from the abundant cytosolic protein calprotectin.

10 own to inhibit the antimicrobial activity of calprotectin.

11 response is the manganese-chelating protein calprotectin.

12 th excessively high plasma concentrations of calprotectin.

13 lmonella organisms bound to cells expressing calprotectin.

14 s were delayed, however, in cells expressing calprotectin.

15 ction was abrogated by zinc and depletion of calprotectin.

16 microbial activity similar to that of native calprotectin.

17 against Candida albicans similar to that of calprotectin.

18 ning manganese in culture in the presence of calprotectin.

19 sed by the manganese binding immune effector calprotectin.

20 nce of the host nutritional immunity protein calprotectin.

21 roxide dismutase activity in the presence of calprotectin.

22 ier defense via mucosal release of IL-22 and calprotectin.

23 oides was increased in infants with abnormal calprotectin.

24 Exposure to calprotectin (a host protein known to sequester metal io

25 on provided a stool sample to be assayed for calprotectin (a neutrophil-specific marker), and patient

26 To isolate the effects of calprotectin, a calprotectin-negative oral epithelial ce

27 Calprotectin, a heterodimer of MRP8 and MRP14 with antim

28 Epithelial cells expressing calprotectin, a heterodimer of S100A8 and S100A9 protein

29 Calprotectin, a heterodimer of S100A8 and S100A9, is an

30 A major player in this process is calprotectin, a host protein that exerts antimicrobial a

31 Levels of calprotectin, a marker of intestinal inflammation, were

32 mmation and down-regulates the expression of calprotectin, a molecule which influences neutrophil fun

33 We conclude that calprotectin, a potent bacteriostatic agent from a cell

34 icant carbonylation of the S100A9 subunit of calprotectin, a truncated form of Hsp70, actin, and hemo

35 icroscopic and regrowth assays revealed that calprotectin acted in a bacteriostatic fashion against B

36 In a hospital setting, fecal calprotectin added the most diagnostic value to symptoms

37 In this study, we aimed to evaluate fecal calprotectin, alpha-1-antitrypsin (alpha(1)-AT), and ela

38 A review of published calprotectin amino acid sequences revealed the HEXXH mot

39 e also found that TdfH confers resistance to calprotectin, an immune effector protein highly produced

40 Calprotectin, an S100 calcium-binding protein with broad

41 Multiple regression modeling identified calprotectin and alpha(1)-AT concentration as independen

42 Calprotectin and alpha(1)-AT concentrations increased wi

43 Our results showed that fecal calprotectin and alpha(1)-AT levels at the time of diagn

44 In contrast, calprotectin and alpha(1)-AT were predictors for SR-GVHD

45 r fecal levels of two GVHD severity markers, calprotectin and alpha1-antitrypsin.

46 immunoglobulin (Ig) were measured in serum; calprotectin and anti-toxin B Ig A/G were measured in st

47 completely reversed by specific antibody to calprotectin and by Zn(2+), a cation essential for the g

48 with melioidosis resulted in lower levels of calprotectin and C-reactive protein (P < 0.0001), coinci

49 The median percent reduction of calprotectin and C-reactive protein was 71% for both bio

50 Serum levels of calprotectin and C-reactive protein were significantly h

51 s of intestinal inflammation, such as faecal calprotectin and C-reactive protein, have been recommend

52 ), video capsule endoscopy (VCE), CRP, fecal calprotectin and CDAI.

53 biopsies were collected and used to quantify calprotectin and expression of 12 Wnt-related genes, res

54 gut by overcoming the zinc sequestration of calprotectin and highlight the importance of zinc acquis

55 Fecal markers such as calprotectin and lactoferrin have been studied for their

56 Calprotectin and lactoferrin levels were quantified by s

57 The levels of calprotectin and lactoferrin varied directly with one an

58 of this study was to determine the levels of calprotectin and lactoferrin, 2 microbiostatic proteins,

59 Serum levels of calprotectin and MMP-8 are elevated in patients with AgP

60 eria to evade neutrophil killing mediated by calprotectin and reactive oxygen species.

61 Plasma calprotectin and serum 25 (OH) vitamin D levels were mea

62 bind and invade transfected cells expressing calprotectin and sham transfectants.

63 nscription, and reversed the upregulation of calprotectin and Toll-like receptor (TLR) 4 in inflamed

64 CDAI, CRP, fecal calprotectin and VCE Lewis inflammatory score did not ch

65 vel of C-reactive protein and fecal level of calprotectin) and fecal Proteobacteria.

66 coefficient = 0.49), whereas diarrhea, high calprotectin, and low SCFA production related to death i

67 athogens (n = 15), cytokines (n = 29), fecal calprotectin, and the short-chain fatty acids (SCFAs) bu

68 In conclusion, expression of calprotectin appears to protect epithelial cells in cult

69 In periodontitis, calprotectin appears upregulated and is detected at high

70 ral mucosa, the expression of immunoreactive calprotectin appears upregulated.

71 Serum C-reactive protein and fecal calprotectin are among the best-studied noninvasive biom

72 ein 1 (PGLYRP1), interleukin (IL)-1beta, and calprotectin are associated with CF or reflect concomita

73 erfacial His(3)Asp and His(4) sites of human calprotectin are identified by using Co(II) as a spectro

74 In addition, cells expressing calprotectin are more resistant to detachment mediated b

75 Blood markers and fecal calprotectin are used in the diagnostic workup for infla

76 c curve analysis revealed a high accuracy of calprotectin (area under the curve, 0.94) in the differe

77 These studies highlight Zn sequestration by calprotectin as a key functional arm of NET-mediated kil

78 We identified calprotectin as a lead biomarker of B. pseudomallei infe

79 Change in faecal calprotectin as a marker of intestinal inflammation and

80 We identify the host protein calprotectin as a neutrophil-dependent factor expressed

81 jacks and directly utilizes the host protein calprotectin as a zinc source and thereby evades nutriti

82 Using fecal calprotectin as an example, we provide a framework for b

83 ammation, specifically stool lactoferrin and calprotectin as well as small intestine contrast ultraso

84 idermis and found S100A8-S100A9, also called calprotectin, as the most upregulated proteins, followed

85 s and levels of C-reactive protein and fecal calprotectin), at pediatric gastroenterology units in Is

86 tion of the IL-6-Janus kinase 2 (JAK2)-STAT3-calprotectin axis with FDA-approved drugs, alone and in

87 In physiologic calprotectin, B. burgdorferi is not eliminated by therap

88 aemia and symptomatic adverse events, faecal calprotectin, C-reactive protein, albumin, platelet coun

89 s and markers of inflammation, such as fecal calprotectin, C-reactive protein, and Crohn's disease ac

90 The level of fecal calprotectin can be used only as a prognostic factor for

91 a conventional ELISA setup measuring canine calprotectin (cCP).

92 operating characteristic curve analysis for calprotectin (CFvsC) showed an area under the curve of 0

93 lular pathogens; in the extracellular space, calprotectin chelates Mn and Zn.

94 Faecal calprotectin, colonic biopsies and magnetic resonance en

95 evels of the innate immunity-related markers calprotectin, colony-stimulating factor (CSF)-1, macroph

96 subunit mRNA by RNase protection assays and calprotectin complex by enzyme-linked immunosorbent assa

97 l line was stably transfected to express the calprotectin complex.

98 Calprotectin (complex of S100A8 and S100A9) is the major

99 stigation for intestinal inflammation (fecal calprotectin concentration), HLA-B27 genotyping, and com

100 fidobacterium were inversely correlated with calprotectin concentration, which in turn was associated

101 NDC supplementation did not affect fecal calprotectin concentration.

102 ce range 11-18 micromol/L) and raised plasma calprotectin concentrations (1.4-6.5 g/L, reference rang

103 30 subjects (75%) had increased repeat fecal calprotectin concentrations above the upper limit of nor

104 stant starch (RS) and polydextrose] on fecal calprotectin concentrations and Wnt pathway-related gene

105 necrotising enterocolitis had raised faecal calprotectin concentrations at the time of diagnosis com

106 Calprotectin concentrations of patients with stable graf

107 extrose supplementation did not affect fecal calprotectin concentrations.

108 Recombinant calprotectin, consisting of 2 individual peptide chains

109 These results suggest that intact calprotectin, consisting of a heterodimer of MRP8 and MR

110 How calprotectin contributes to the pathogenesis of periodon

111 cus (GAS) encounters the host defense factor calprotectin (CP) during infection.

112 The S100A8/S100A9 heterodimer calprotectin (CP) functions in the host response to path

113 Calprotectin (CP) is a transition metal-chelating antimi

114 Calprotectin (CP) is an antimicrobial protein produced a

115 Human calprotectin (CP) is an antimicrobial protein that coord

116 The antimicrobial protein calprotectin (CP), a hetero-oligomer of the S100 family

117 ron withholding by the innate immune protein calprotectin (CP).

118 Human calprotectin (CP, S100A8/S100A9 oligomer) is a metal-seq

119 The human innate immune protein calprotectin (CP, S100A8/S100A9 oligomer, calgranulin A/

120 Human calprotectin (CP, S100A8/S100A9 oligomer, MRP-8/MRP-14 o

121 Here, we report that human calprotectin (CP; S100A8/S100A9 or MRP8/MRP14 heteroolig

122 Levels of calprotectin, CSF-1, MIF, MIG, and MMP-8 were measured u

123 atus, intestinal mucosal inflammation (fecal calprotectin), daily morbidity, and cognitive developmen

124 l burdens in the livers of wild-type but not calprotectin-deficient mice, suggesting that these syste

125 ureus This defect is partially reversed in a calprotectin-deficient mouse, in which manganese is more

126 rrent study, we showed that neutrophils from calprotectin-deficient S100A9(-/-) mice have an impaired

127 The abundant PMN cytoplasmic protein calprotectin, elevated 10- to 100-fold in inflammation,

128 crobial communities are found to co-exist in calprotectin-enriched airspaces of a cystic fibrosis lun

129 Similarly, binding to calprotectin expressing cells was reduced approximately

130 Calprotectin-expressing and sham-transfected cells showe

131 Calprotectin-expressing cells appeared to have internali

132 Listeria organisms bound to the surfaces of calprotectin-expressing cells, and 10-fold fewer were lo

133 supplemented direct antimicrobial effects in calprotectin-expressing cells.

134 acterial pathogens showed reduced binding to calprotectin-expressing epithelial cells.

135 Calprotectin-expressing transfectants expressed calprote

136 In this study, we assessed whether calprotectin expression affects bacterial binding and up

137 Calprotectin expression was accompanied by altered actin

138 Calprotectin expression was constitutive in the primary

139 To test whether calprotectin expression was inducible, immortalized ging

140 In addition, faecal calprotectin, faecal zonulin and serum lipopolysaccharid

141 estigated whether monitoring levels of fecal calprotectin (FC) can substitute for endoscopic analysis

142 Serum and mucosal ST2, and fecal calprotectin (FC) content were determined by ELISA and c

143 Faecal calprotectin (FC) is one of the most widely used non-inv

144 Faecal calprotectin (FC), Gastrointestinal Symptoms Rating Scal

145 The performances of faecal calprotectin (fcal), clinical and serologic parameters i

146 ationship between the concentration of fecal calprotectin (FCP) and clinical and endoscopic outcomes

147 Fecal calprotectin (FCP), magnetic resonance enterography (MRE

148 ccuracy of more than 1 blood marker or fecal calprotectin for IBD, confirmed by endoscopy and histopa

149 MntABC and MntH compete with calprotectin for manganese, which enables S. aureus grow

150 50 mg/L, the sensitivity and specificity of calprotectin for predicting relapse in all patients with

151 The AUC of baseline faecal calprotectin for the prediction of flare occurring withi

152 100A8-A9 in fecal samples (also called fecal calprotectin) from newborns and during infancy, and thei

153 al epithelial cell line was transfected with calprotectin genes to enable expression.

154 p before and after random assignment: faecal calprotectin >/=250 mug/g, C-reactive protein >/=5mg/L,

155 L, C-reactive protein >/=5.0 mg/L, and fecal calprotectin >/=300 mug/g.

156 on, we show that the Zn-binding S100 protein calprotectin has antimicrobial effects against C. diffic

157 Calprotectin has been proposed as a useful marker of inf

158 Fecal level of calprotectin has not been validated as a biomarker for I

159 Urinary calprotectin has recently been identified as a promising

160 function of the innate immune protein human calprotectin (hCP) has broadened in recent years, unders

161 The best marker-fecal calprotectin-improved the area under the curve of sympto

162 Among fecal tests, fecal calprotectin in a range of 50-60 mug/g (pooled sensitivi

163 The use of faecal calprotectin in addition to EPAGE criteria improved diag

164 The use of faecal calprotectin in addition to EPAGE criteria improved the

165 We evaluated the diagnostic value of fecal calprotectin in patients with abdominal discomfort.

166 adult KD cohorts revealed elevated levels of calprotectin in pediatric patients with giant CAA 1 year

167 We measured calprotectin in plasma and protein fractions by ELISA as

168 Immunohistochemical stainings for calprotectin in renal allograft biopsy specimens confirm

169 ught to learn if epithelial cells upregulate calprotectin in response to proinflammmatory agents.

170 osal epithelial cells constitutively express calprotectin in the cytoplasm.

171 me in the azurophil granule compartment; and calprotectin in the cytosolic compartment.

172 t to hyphae, we found no role for neutrophil calprotectin in uptake or killing of intracellular A. fu

173 and following incubation with neutrophils or calprotectin in vitro as compared with wild-type.

174 00A8/A9 [myeloid-related protein (MRP) 8/14, calprotectin] in promoting glomerulonephritis.

175 ltration initiating colitis with lesions and calprotectin increase.

176 All blood markers and fecal calprotectin individually significantly improved the dis

177 studies of bone marrow-derived MPhis showed calprotectin-induced CCL11 production via a p65-dependen

178 Neutrophil-derived calprotectin inhibited S. aureus growth through chelatio

179 These results demonstrate that calprotectin is a critical factor in the innate immune r

180 ity." The manganese and zinc binding protein calprotectin is a key component of the nutrient-withhold

181 Urinary calprotectin is a promising biomarker for the differenti

182 Calprotectin is a protein in neutrophil cytoplasm and ab

183 In patients with abdominal discomfort, fecal calprotectin is a useful non-invasive marker to identify

184 The present study investigates whether calprotectin is able to differentiate between these 2 en

185 We find that while calprotectin is induced by neutrophils during infection

186 in surrounds staphylococcal heart abscesses, calprotectin is not released into the abscess nidus and

187 ctivity of polyhistidine, as well as that of calprotectin itself, was reversed by addition of zinc or

188 We investigated fecal calprotectin level (FCL) as a candidate noninvasive mark

189 profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation).

190 Calprotectin levels (n = 68) were measured in this pilot

191 nificantly higher BOP scores (P = 0.001) and calprotectin levels (P = 0.017) compared with the C grou

192 Increased calprotectin levels activate signaling pathways involved

193 Low stool calprotectin levels correlate well with a low risk for i

194 Median calprotectin levels decreased by 40% in response to anti

195 Median stool calprotectin levels from patients with rejection were si

196 We measured calprotectin levels in 732 stool samples collected, anal

197 s, in combination with publications on fecal calprotectin levels in patients with IBD.

198 ric and adult KD cohorts identified elevated calprotectin levels in the plasma of patients with CAA.

199 Median calprotectin levels in the relapse groups (122 mg/L for

200 Calprotectin levels positively correlated with procalcit

201 tients with serial levels, elevations in the calprotectin levels preceded histologic changes by 6 to

202 ection episodes have greater fluctuations in calprotectin levels than those without, suggesting incre

203 Median calprotectin levels were higher (81.5 mug/g, interquarti

204 Median calprotectin levels were higher in patients with melioid

205 Median calprotectin levels were higher in patients with signifi

206 Thus, reductions in serum calprotectin levels were linked to therapeutic responses

207 Salivary calprotectin levels were not associated with periodontal

208 er gingival inflammation scores and salivary calprotectin levels, that correlated with systemic infla

209 genic culture, clinical diagnosis, and fecal calprotectin levels.

210 gged with six C-terminal histidines did have calprotectin-like zinc-reversible antimicrobial activity

211 tive protein <=0.5 mg/dL, and level of fecal calprotectin <=150 mug/g compared with 5 patients in the

212 In periodontal disease, calprotectin may augment both the barrier protection and

213 Our results suggest that calprotectin may be a sensitive indicator of melioidosis

214 Calprotectin may modify the clearance of spirochetes at

215 Calprotectin may serve as a biomarker to inform the mana

216 th significant concurrent decreases in fecal calprotectin (mean decrease 918 +/- 555 mg/kg; P = .002)

217 the sensitivity of Staphylococcus aureus to calprotectin-mediated manganese sequestration.

218 ity to CDI and severity of disease, and that calprotectin-mediated metal limitation is an important f

219 ith the gut pathogen Salmonella Typhimurium, calprotectin-mediated metal sequestration does not inhib

220 Calprotectin-mediated Mn sequestration is a newly apprec

221 Remarkably, S. Typhimurium overcomes calprotectin-mediated zinc chelation by expressing a hig

222 Calprotectin mediates the cytoplasmic activity, whereas

223 Faecal calprotectin might be a useful marker of gastrointestina

224 , preliminary data demonstrate that salivary calprotectin might have a chairside diagnostic potential

225 ejection, based on these data, routine stool calprotectin monitoring is not strongly supported.

226 Elevated levels of plasma calprotectin months to decades after acute KD and infilt

227 These data show that calprotectin mRNA is expressed constitutively in culture

228 PCE also induced the secretion of calprotectin (myeloid-related protein 8/14 [MRP8/14] com

229 e, we show activation of neutrophil markers, Calprotectin, Myeloperoxidase (MPO), and IL-8 are signif

230 cal biomarkers of environmental enteropathy (calprotectin, myeloperoxidase, alpha1-antitrypsin) and t

231 Other proteins identified, including calprotectin, myeloperoxidase, and alpha-defensins, are

232 00A9 encoding plasmids were transfected into calprotectin-negative KB carcinoma cells.

233 To isolate the effects of calprotectin, a calprotectin-negative oral epithelial cell line was tran

234 protectin-expressing transfectants expressed calprotectin on the cell surface as well as in the cytos

235 We did not find increased fecal calprotectin or IgA as marker of inflammation in childre

236 k showed that the S100A8/S100A9 heterodimer (calprotectin, or calgranulin A/B) binds zinc and repress

237 markers such as leukocytes, lactoferrin, or calprotectin, or positive stool culture for an invasive

238 GCF Calprotectin, osteocalcin, and N-telopeptide of type I c

239 Wolbachia DNA and the antibacterial peptides calprotectin (P =.021) and calgranulin B (P <.0001).

240 tive components such as soluble defensin and calprotectin peptides.

241 Calprotectin-positive neutrophils were abundant in regio

242 Fecal calprotectin predicts clinical relapse of disease activi

243 's disease involving the small bowel, faecal calprotectin predicts short-term flare risk, whereas VCE

244 crine stimulus to increase S100A8/9 complex (calprotectin) production and secretion.

245 nsistent with these results, the presence of calprotectin promotes co-colonization of the murine lung

246 loss of the calcium-induced positive face in calprotectin, reducing interactions with microtubules an

247 Cells expressing calprotectin resist invasion by Listeria monocytogenes a

248 ) mutants or the S100A9(1-114) (full-length) calprotectin resisted bacterial invasion better than KB-

249 , these data provide a working model whereby calprotectin responds to physiological Ca(II) gradients

250 zinc and manganese binding are necessary for calprotectin's antihyphal activity.

251 These results suggest that calprotectin's antimicrobial activity may be related to

252 two effector antimicrobial peptides (AMPs): calprotectin (S100A8-S100A9 heterodimer [S100A8/A9]) in

253 alyses revealed a link between expression of calprotectin (S100a8/S100a9), Ccl11 expression, and eosi

254 Calprotectin sequesters essential micronutrient metals s

255 uses specialized metal transporters to evade calprotectin sequestration of manganese, allowing the ba

256 lood cell count, C-reactive protein or fecal calprotectin, serologic testing for celiac disease, and

257 C-reactive protein, fecal lactoferrin, fecal calprotectin, serologic tests for celiac disease, tests

258 Transfected cells expressing calprotectin showed 40 to 50% fewer internalized P. ging

259 en of the disease (C-reactive protein, fecal calprotectin) since symptoms-based scores are subjective

260 e in the primary gingival keratinocytes, but calprotectin-specific mRNA and protein tended to increas

261 flamed prostate epithelium; however, IHC for calprotectin suggested prostate-infiltrating neutrophils

262 canonical mammalian Mn-sequestering protein calprotectin surrounds staphylococcal heart abscesses, c

263 ent a baseline capsule enteroscopy and fecal calprotectin test.

264 h rejection have higher mean levels of stool calprotectin than those without, but because of signific

265 00A9) form MRP-8/14 heterodimers (S100A8/A9, calprotectin) that regulate myeloid cell function and in

266 Faecal calprotectin, thyroid tests, celiac serology, breath tes

267 e use of inflammatory markers, such as fecal calprotectin to detect SIBO.

268 d the incremental diagnostic value of faecal calprotectin to EPAGE criteria.

269 ng release of antimicrobial proteins such as calprotectin to inhibit bacterial growth.

270 We assessed the validity of fecal calprotectin to serve as a surrogate biomarker of IBD ac

271 Adding fecal calprotectin to the diagnostic workup of pediatric patie

272 ed expression of both systems in response to calprotectin treatment.

273 Final endoscopic diagnoses were blinded to calprotectin values.

274 Final diagnoses were adjudicated blinded to calprotectin values.

275 ved that metal content and the importance of calprotectin varies between murine organs, and infection

276 l ion starvation mediated by lipocalin-2 and calprotectin via alternative pathways, IL-22 boosted its

277 cases and 120 controls, increased levels of calprotectin, von Willebrand factor, angiotensinogen, IL

278 Median urinary calprotectin was 36 times higher in intrinsic AKI (1955

279 When fecal calprotectin was added to the model, the proportion of p

280 Urinary calprotectin was assessed by enzyme-linked immunosorbent

281 Calprotectin was measured and fecal DNA was sequenced us

282 Plasma calprotectin was measured by ELISA in 28 pediatric KD pa

283 Faecal calprotectin was measured in stool samples collected wit

284 Calprotectin was measured in stool samples collected wit

285 ia activity of U-Cyt lysates and recombinant calprotectin was partially or completely reversed by spe

286 Calprotectin was significantly higher in children who di

287 Fecal calprotectin was useful as a diagnostic parameter both f

288 In serum, mean levels of calprotectin were 2.06-fold higher in patients with AgP

289 Salivary TREM-1, PGLYRP1, IL-1beta, and calprotectin were analyzed by enzyme-linked immunosorben

290 xclusion chromatography showed that zinc and calprotectin were associated in a broad fraction with mo

291 The abscesses of mice lacking calprotectin were enriched in metal, and staphylococcal

292 ved CD-TREAT and their clinical activity and calprotectin were evaluated after 8 weeks of treatment.

293 Fecal samples were collected, levels of calprotectin were measured, and microbiota were analyzed

294 unoassay (EIA), toxigenic culture, and fecal calprotectin were performed.

295 We found that TdfH directly binds calprotectin, which enables gonococcal Zn accumulation i

296 icrobial proteins, including lipocalin-2 and calprotectin, which sequester essential metal ions from

297 ts with HCC showed increased levels of fecal calprotectin, while intestinal permeability was similar

298 radshaw index, C-reactive protein and faecal calprotectin will be collected at recruitment and 3 mont

299 Furthermore, using recombinant calprotectin with mutations in either the Zn and Mn bind

300 of the IL-22 inducible antimicrobial protein calprotectin without modulating IL-17 expression.